上海医药(02607.HK)斥3,006万美元设合营从事生物技术开发等业务
上海医药(02607.HK)公布,集团全资子公司SPH PB出资3,006万美元与BIOCAD HK签署关於合资新设SPH-BIOCAD(HK)的股东协议,占合资公司50.1%股权。
合资公司将主营生物技术、实验室设备技术领域内的技术开发,技术服务,技术谘询,技术转让,以及生产和销售自产抗体类及蛋白类药物等,将不涉及外商投资准入负面清单中列明的特别管理措施领域。
集团指,股东双方後续将向合资公司分别注入大分子生物创新药、生物类似药及现金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.